Bonjesta is developed by Duchesnay Inc..

What development phase is Bonjesta in?

Bonjesta is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Bonjesta

Duchesnay Inc. · FDA-approved active Small molecule Quality 2/100

Bonjesta, marketed by Duchesnay Inc., is a pharmaceutical product with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging the patent protection to maintain exclusivity. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic name	Bonjesta
Sponsor	Duchesnay Inc.
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Bonjesta CI brief — competitive landscape report
Bonjesta updates RSS · CI watch RSS
Duchesnay Inc. portfolio CI